Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $100.80 | 6 | 59.0% |
| Debt forgiveness | $69.96 | 1 | 41.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Baxter Healthcare | $69.96 | 1 | $0 (2022) |
| Genentech USA, Inc. | $42.32 | 3 | $0 (2019) |
| Esperion Therapeutics, Inc. | $27.56 | 1 | $0 (2021) |
| Exact Sciences Corporation | $19.53 | 1 | $0 (2024) |
| Janssen Biotech, Inc. | $11.39 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $19.53 | 1 | Exact Sciences Corporation ($19.53) |
| 2022 | $69.96 | 1 | Baxter Healthcare ($69.96) |
| 2021 | $27.56 | 1 | Esperion Therapeutics, Inc. ($27.56) |
| 2019 | $43.19 | 3 | Genentech USA, Inc. ($31.80) |
| 2018 | $10.52 | 1 | Genentech USA, Inc. ($10.52) |
All Payment Transactions
7 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/03/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $19.53 | General |
| Category: Oncology | ||||||
| 01/06/2022 | Baxter Healthcare | — | Debt forgiveness | In-kind items and services | $69.96 | General |
| 04/09/2021 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $27.56 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 12/23/2019 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $14.49 | General |
| Category: Virology & Specialty Care | ||||||
| 11/07/2019 | Janssen Biotech, Inc. | SIMPONI (Biological) | Food and Beverage | In-kind items and services | $11.39 | General |
| Category: Immunology | ||||||
| 04/18/2019 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $17.31 | General |
| Category: Virology & Specialty Care | ||||||
| 11/16/2018 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $10.52 | General |
| Category: Virology & Specialty Care | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 716 | 802 | $88,755 | $44,676 |
| 2022 | 21 | 1,072 | 1,211 | $122,494 | $72,629 |
| 2021 | 16 | 1,414 | 1,617 | $164,972 | $111,821 |
| 2020 | 15 | 1,930 | 2,074 | $216,615 | $135,223 |
All Medicare Procedures & Services
68 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 173 | 208 | $28,800 | $13,587 | 47.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 84 | 104 | $17,800 | $10,399 | 58.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 67 | 67 | $13,120 | $5,504 | 42.0% |
| 0241U | Respiratory infectious agent detection by rna for severe acute respiratory syndrome coronavirus 2 (covid 19), influenza a, influenza b, and respiratory syncytial virus, upper respiratory specimen, each reported as detected or not detected | Office | 2023 | 24 | 24 | $4,800 | $3,355 | 69.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 25 | 25 | $4,370 | $3,238 | 74.1% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2023 | 52 | 53 | $6,625 | $2,665 | 40.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 18 | 18 | $4,950 | $2,421 | 48.9% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 22 | 23 | $2,090 | $594.32 | 28.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 57 | 70 | $700.00 | $588.00 | 84.0% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 26 | 26 | $650.00 | $478.14 | 73.6% |
| 87651 | Detection test by nucleic acid for strep (streptococcus, group a), amplified probe technique | Office | 2023 | 12 | 12 | $1,200 | $412.68 | 34.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 30 | 35 | $1,080 | $394.80 | 36.6% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2023 | 12 | 12 | $600.00 | $383.38 | 63.9% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 40 | 40 | $924.80 | $355.55 | 38.4% |
| 81002 | Urinalysis, manual test | Office | 2023 | 61 | 72 | $720.00 | $245.52 | 34.1% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2023 | 13 | 13 | $325.00 | $55.20 | 17.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 353 | 430 | $56,470 | $33,899 | 60.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 84 | 94 | $15,250 | $9,490 | 62.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 100 | 100 | $15,160 | $9,468 | 62.5% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 63 | 63 | $7,140 | $4,689 | 65.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 69 | 69 | $5,600 | $3,917 | 69.9% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2022 | 43 | 45 | $5,625 | $2,271 | 40.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 14 | 14 | $3,060 | $1,958 | 64.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 11 | 11 | $1,925 | $1,460 | 75.9% |
| 71046 | X-ray of chest, 2 views | Office | 2022 | 34 | 35 | $2,275 | $966.91 | 42.5% |
About Dr. Supak Sookkasikon, M.D
Dr. Supak Sookkasikon, M.D is a Family Medicine healthcare provider based in Bloomfield Township, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1649376922.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Supak Sookkasikon, M.D has received a total of $170.76 in payments from pharmaceutical and medical device companies, with $19.53 received in 2024. These payments were reported across 7 transactions from 5 companies. The most common payment nature is "Food and Beverage" ($100.80).
As a Medicare-enrolled provider, Sookkasikon has provided services to 5,132 Medicare beneficiaries, totaling 5,704 services with total Medicare billing of $364,349. Data is available for 4 years (2020–2023), covering 68 distinct procedure/service records.
Practice Information
- Specialty Family Medicine
- Location Bloomfield Township, MI
- Active Since 09/15/2006
- Last Updated 02/28/2014
- Taxonomy Code 207Q00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1649376922
Products in Payments
- Xofluza (Drug) $42.32
- NEXLETOL (Drug) $27.56
- Cologuard Collection Kit (Device) $19.53
- SIMPONI (Biological) $11.39
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.